New perspectives in pharmacological treatment of mild persistent asthma

Paolo Montuschi, Pj Barnes

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

48 Citazioni (Scopus)

Abstract

Until the relationship between symptoms, lung function tests, airway inflammation, airway hyper-responsiveness (AHR), exacerbations and remodelling is clarified, regular treatment seems to enable a greater disease control than on-demand therapy in most patients with mild persistent asthma. Current guideline classification based on disease severity remains a cornerstone in asthma management. However, the heterogeneity of asthma, the growing emphasis on subphenotypes, including molecular phenotypes identified by -omics technologies, and their possible implications in terms of different asthma severity, progression and therapeutic response, are changing current asthma treatment mainly based on disease severity classification to a pharmacological strategy more focused on the individual patient.
Lingua originaleEnglish
pagine (da-a)1084-1091
Numero di pagine8
RivistaDrug Discovery Today
Volume16
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Airway inflammation
  • Airway remodelling
  • Asthma
  • Inflammatory biomarkers
  • Inhaled corticosteroids
  • Pharmacological treatment

Fingerprint Entra nei temi di ricerca di 'New perspectives in pharmacological treatment of mild persistent asthma'. Insieme formano una fingerprint unica.

Cita questo